Go to Health Care Provider version
| Diagnosis | All solid tumours, all brain tumours, lymphomas | Study Status | Closed to enrollment |
| Phase | I |
| Age | Child, Adult - (2 years to 25 years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | CLR 131 administered intravenously, single or fractionated dose |
| Last Posted Update | 2023-02-09 |
| ClinicalTrials.gov # | NCT03478462 |
International Sponsor
Cellectar Biosciences, Inc.Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel MorgensternCentres
Study Description
This clinical trial studies the side effects of a medication called CLR131. This medication is a targeted radiopharmaceutical, which means it acts like radiation therapy, but is given intravenously as an infusion.
CLR 131 is designed to target cells with cancer rather than cells without cancer. The main goal of this study is to determine what is the safe amount of medication to give to children with cancer that has come back or is not responding to treatment.
Inclusion Criteria
- Age between 2 and 25 years
- All cancers (except leukemia) that have come back (relapse) or not improved despite treatment (progression)
- Patients need to undergo blood stem cell collection or have those cells available from a previous collection
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
